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Abstract
Background: The occurrence of bloodstream infection (BSI) and antimicrobial resistance have been increasing in
many countries. We studied trends in antimicrobial resistance and empiric antibiotic therapy at a medium-sized
general hospital in Mid-Norway.
Methods: Between 2002 and 2013, 1995 prospectively recorded episodes of BSI in 1719 patients aged 16–99 years
were included. We analyzed the antimicrobial non-susceptibility according to place of acquisition, site of infection,
microbe group, and time period.
Results: There were 934 community-acquired (CA), 787 health care-associated (HCA) and 274 hospital-acquired
(HA) BSIs. The urinary tract was the most common site of infection. Escherichia coli was the most frequently isolated
infective agent in all three places of acquisition. Second in frequency was Streptococcus pneumoniae in CA and
Staphylococcus aureus in both HCA and HA. Of the BSI microbes, 3.5% were non-susceptible to the antimicrobial
regimen recommended by the National Professional Guidelines for Use of Antibiotics in Hospitals, consisting of
penicillin, gentamicin, and metronidazole (PGM). In contrast, 17.8% of the BSI microbes were non-susceptible to
cefotaxime and 27.8% were non-susceptible to ceftazidime.
Antimicrobial non-susceptibility differed by place of acquisition. For the PGM regimen, the proportions of
non-susceptibility were 1.4% in CA, 4.8% in HCA, and 6.9% in HA-BSI (p < 0.001), and increasing proportions
of non-susceptibility over time were observed in HA-BSI, 2.2% in 2002–2005, 6.2% in 2006–2009, and 11.7%
in 2010–2013 (p = 0.026), mainly caused by inherently resistant microbes. We also observed increasing numbers of
bacteria with acquired resistance, particularly E. coli producing ESBL or possessing gentamicin resistance, and these
occurred predominantly in CA- and HCA-BSI.
Conclusions: Generally, antimicrobial resistance was a far smaller problem in our BSI cohort than is reported from
countries outside Scandinavia. In our cohort, appropriate empiric antibiotic therapy could be achieved to a larger
extent by replacing second- and third-generation cephalosporins with penicillin-gentamicin or piperacillin-tazobactam.
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Background
Bloodstream infection (BSI) contributes substantially to
morbidity and mortality worldwide [1]. In Europe, the an-
nual number of BSI episodes and deaths associated with
BSI has been estimated to 1.2 million and 157,000, respect-
ively [1]. Early diagnosis and early appropriate treatment is
crucial. In severe sepsis, the case fatality increases for each
hour the antibiotic treatment is delayed [2, 3]. Therefore,
empirical antibiotic treatment has to be initiated before the
results of blood cultures are available. However, as infec-
tions with resistant microbes is an escalating problem
worldwide [4–6], it is increasingly challenging to maintain
appropriate antibiotic regimens for initial empiric therapy.
Resistant pathogenic bacteria are found less frequently in
Norway and other Nordic countries, compared to the rest
of Europe and other world regions [7, 8]. This probably re-
flects a relatively restrictive use of antimicrobial agents. In
Norway, a regimen containing penicillin and gentamicin
(PG), plus metronidazole (PGM) if an anaerobic infection is
suspected, has been recommended for more than thirty
years in sepsis with unknown focus and etiology [9–11]. In
recent years, however, increasing numbers of infections
with methicillin-resistant Staphylococcus aureus (MRSA),
extended-spectrum beta-lactamase producing Enterobacte-
riaceae (ESBL-E), and vancomycin resistant enterococci
have been detected [8]. Selection of inherently resistant mi-
crobes due to antibiotic use is also a challenge. Updated
knowledge about the distribution of microbes in serious in-
fections and their resistance against antimicrobial agents is
needed to ensure appropriate empiric antimicrobial treat-
ment regimens. It is also important to identify subgroups in
which tailored regimens are required. Important differences
in antibiotic resistance have been found with regard to
place of acquisition [12, 13], and therefore, resistance statis-
tics should specify results for community acquired (CA),
health care-associated (HCA), and hospital acquired (HA)
infections.
We conducted a prospective study to assess the occur-
rence and distribution of BSI microbes and their non-
susceptibility to some common antibiotic regimens for
initial empiric antimicrobial treatment of sepsis of un-
known etiology. Particularly, we assessed microbes and
antimicrobial resistance by place of acquisition (CA, HCA
and HA-BSIs) and with regard to time trends over a
12-year period. We also studied the antibiotic regimens
that were used for initial empiric treatment during the
same time period and the degree to which they were
appropriate.
Methods
Levanger Hospital serves a population of about 90,000
as an emergency facility in a defined geographical area
of Mid-Norway. Since 1994, all positive blood cultures at
the hospital have been prospectively recorded for
surveillance purposes, and clinical information has been
recorded, in the following way: whenever a positive
blood culture was reported, a physician at the clinical
ward filled out a registration form. A team of three
research nurses, two subordinate doctors, and the main
investigator reviewed all patients’ records to verify the
data and record additional variables. The present study
includes BSIs that occurred between January 1, 2002 and
December 31, 2013 in patients who were ≥16 years of
age, and it is part of the Mid-Norway Sepsis Study.
The microbiology laboratory at Levanger Hospital is ISO
15189 accredited and participates in the national quality
assurance schemes (ring tests). Blood cultures were
performed in BACTEC 9240 Vacutainer Culture Bottles
(Becton Dickinson Diagnostic Instrument Systems, Sparks,
MD) [14], which in 2010 was replaced by BACTEC FX. No
obvious changes in blood culture techniques or indications
for drawing blood cultures have been done during the study
period, but an increased focus on early detection of sepsis
may have influenced the rate of blood culture sampling.
Over the study period, the number of blood culture sets
per 1000 hospital bed-days increased from 25.0 in 2002 to
59.5 in 2013.
Isolates were identified using standard methods [15].
Antimicrobial susceptibility testing was performed by
the disc diffusion method (Neo-Sensitabs, Rosco Diagnos-
tica, Taastrup, Denmark). For measurement of MIC, E-test
(AB Biodisk, Solna, Sweden) was used. The results of anti-
bacterial susceptibility testing were interpreted according to
the Norwegian Working Group on Antibiotics (NWGA).
For the antibiotics included in this study, the Norwegian
breakpoints correspond to EUCAST (European Committee
on Antimicrobial Susceptibility Testing) breakpoints
[8, 16]. In this study, microbes intermediately suscep-
tible to antibiotics were classified as non-susceptible
[17–19], as only susceptible microbes can be regarded
as being able to be managed by means of the respective
antibiotic regimens. Microbes not tested in the laboratory
because of known inherent non-susceptibility (e.g. entero-
cocci are inherently resistant to cephalosporins) were classi-
fied as non-susceptible (see Additional file 1: Appendix 1
On inherent (natural) resistance in microbes).
An episode of BSI was defined by growth of one or
more microbes from blood culture combined with clinical
evidence of systemic infection. A new BSI episode with
the same microbe in the same patient was recorded if an
interval of at least 30 days had passed without signs of
infection since an earlier episode [20]. If more than one
organism was isolated from one or more blood cultures
within a 72-h period, the BSI episode was classified as
polymicrobial. One positive blood culture for organisms
usually regarded as etiological agents was the requirement
for inclusion. For coagulase-negative staphylococci or
other possible skin contaminants, at least two identical
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isolates from separate venipunctures were required.
Among alpha-hemolytic streptococci, S. pneumoniae and
streptococci belonging to the S. milleri group were not
considered as skin contaminants. Other alpha-hemolytic
streptococci were included if they were found in two or
more blood cultures from different venipuncture sites.
The place of acquisition was classified as hospital-
acquired (HA), health care-associated (HCA) or commu-
nity acquired (CA) [12, 21]. HA-BSI was diagnosed if the
infection was detected >48 h after admission [22]. Patients
who during the 30 days prior to hospital admission had (1)
been hospitalized two or more days or (2) had received
intravenous therapy or wound care at home or (3)
hemodialysis or chemotherapy at hospital visits or (4) were
nursing home residents, were categorized as having HCA-
BSI. CA-BSI was diagnosed if the infection was detected
<48 h after admission and none of the criteria for HCA-BSI
were fulfilled.
A urinary focus was assigned when there was growth of
the same microbe (s) from urine as well as from blood
culture along with clinical signs/symptoms or risk factor
for urinary infection, and no other source of infection was
identified. A presumed pulmonary focus was diagnosed
with clinical signs of lower respiratory infection accom-
panied by positive radiological findings. Focus in the
biliary tract was ascertained based on clinical, biochemical
and radiological findings. Signs of infection along with
focal growth of the same microbe as in blood culture were
Table 1 Bloodstream infection (BSI) episodes in three time periods
Total 2002–2005 2006–2009 2010–2013
All BSIs 1995 (100,0) 582 (100.0) 638 (100.0) 775 (100.0)
Place of acquisition
Community acquired 934 (46.8) 317 (54.5) 280 (43.9) 337 (43.5)
Health care-associated 787 (39.4) 175 (30.1) 277 (43.4) 335 (43.2)
Hospital acquired 274 (13.7) 90 (15.5) 81 (12.7) 103 (13.3)
Microbial agent(s)
Escherichia coli 686 (34.4) 186 (32.0) 231 (36.2) 269 (34.7)
Streptococcus pneumoniae 225 (11.3) 80 (13.8) 80 (12.5) 65 (8.4)
Staphylococcus aureus 218 (10.9) 72 (12.4) 55 (8.6) 91 (11.7)
Klebsiella spp. 135 (6.8) 22 (3.8) 44 (6.9) 69 (8.9)
Beta-hemolytic streptococci 104 (5.2) 33 (5.7) 35 (5.5) 36 (4.6)
Enterococcus spp. 89 (4.5) 28 (4.8) 26 (4.1) 35 (4.5)
Other mixed bacterial infections 68 (3.4) 21 (3.6) 19 (3.0) 28 (3.6)
Pseudomonas spp. 58 (2.9) 20 (3.4) 21 (3.3) 17 (2.2)
Viridans group streptococci 57 (2.9) 15 (2.6) 19 (3.0) 23 (3.0)
Coagulase-negative staphylococci 54 (2.7) 23 (4.0) 11 (1.7) 20 (2.6)
Proteus spp. 48 (2.4) 17 (2.9) 15 (2.3) 16 (2.1)
Anaerobic Gram-negative bacteria 45 (2.3) 14 (2.4) 16 (2.5) 15 (1.9)
Mixed Gram-negative aerobic or anaerobic bacteria 42 (2.1) 13 (2.2) 11 (1.7) 18 (2.3)
Enterobacter spp. 37 (1.9) 8 (1.4) 14 (2.2) 15 (1.9)
Other Enterobacteriaceae 37 (1.9) 7 (1.2) 12 (1.9) 18 (2.3)
Other aerobic Gram-negative bacteria 19 (1.0) 5 (0.9) 4 (0.6) 10 (1.3)
Haemophilus influenzae 17 (0.9) 6 (1.0) 8 (1.3) 3 (0.4)
Candida spp. 14 (0.7) 1 (0.2) 4 (0.6) 9 (1.3)
Anaerobic Gram-positive bacteria 11 (0.6) 3 (0.5) 4 (0.6) 4 (0.5)
Mixed gram-positive aerobic or anaerobic bacteria 11 (0.6) 1 (0.2) 4 (0.6) 6 (0.8)
Neisseria meningitidis 9 (0.5) 4 (0.7) 2 (0.3) 3 (0.4)
Listeria monocytogenes 8 (0.4) 2 (0.3) 2 (0.3) 4 (0.5)
Mixed bacterial and fungal infections 3 (0.2) 1 (0.2) 1 (0.2) 1 (0.1)
The table shows number (percent) of BSIs overall, by place of acquisition, and by microbial agent(s)
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taken as a confirmation of infection in abdomen, skin, soft
tissue or other sites. An unknown focus of infection was
assigned when none of the criteria for ascertaining a focus
were met.
Appropriate empiric antibiotic therapy (AEAT) was
defined as correctly dosed intravenous antibiotic therapy
with a regimen that was active in vitro against the
microbe(s) isolated from blood culture (s). We assessed
AEAT within 6 h and within 24 h of the time that the
blood culture specimen was obtained.
Statistical analyses
Proportions of non-susceptibility across place of acquisition
categories and time periods were assessed by a two-sided
chi-square test. Trends in proportions were analyzed using
Cochran-Armitage test. Two-sided p-values <0.05 were
considered significant. Confidence intervals were calculated
using Wilson’s approximation to the binominal distribution
[23]. The analyses were performed using SPSS 22, STATA
13, and StatXact 9.
Results
During the 12-year study period, a total of 1995 episodes
of BSI occurred among 1719 individuals. CA-BSI
episodes amounted to 46.8% of the total, HCA- and HA-
BSI contributed 39.4% and 13.7%, respectively (Table 1).
Escherichia coli was the predominating microbe (34.4%),
followed by Streptococcus pneumoniae (11.3%) and
Staphylococcus aureus (10.9%). The distribution of microbes
by place of acquisition is shown in Fig. 1 and Additional
file 1: Table S1. The distribution of microbes by infection
site is shown in Additional file 1: Table S2. Totally, the
number of BSIs increased across the three 4-year periods
2002–2005, 2006–2009, and 2010–2013 (Table 1). Most
microbes contributed essentially similar proportions of
the BSIs in each of the three time periods. However, the
proportions of BSI from Klebsiella spp. (3.8% vs. 8.9%)
and Candida spp. (0.3% vs. 1.3%) increased from the
first to the third period. Conversely, the proportion of
BSI from Streptococcus pneumoniae decreased from
13.8 to 8.4%.
In vitro susceptibility to antibiotics
Overall, 6.1% of the microbes were non-susceptible to a
regimen consisting of penicillin and gentamicin (PG),
and 3.5% were non-susceptible to a triple agent regimen
including penicillin, gentamicin, and metronidazole
(PGM) (Table 2). The proportions not susceptible to
imipenem, piperacillin-tazobactam (PIP/TAZ), and cefo-
taxime, were 4.5%, 7.6%, and 17.8%, respectively. A
broad-spectrum combination containing PIP/TAZ, gen-
tamicin, and metronidazole had the lowest degree of
non-susceptibility (2.6%), whereas ceftazidime had the
highest (27.8%) (Table 2).
The non-susceptibility to PGM was higher in HA-BSI
(6.9%) and HCA-BSI (4.8%) than in CA-BSI (1.4%)
(p < 0.001). Similar differences across place of acqui-
sition were seen for imipenem, PIP/TAZ, and cefotaxime
(Fig. 2, Table 2, Additional file 1: Table S3). The proportions
of microbes non-susceptible to PGM increased through
the three time periods in HA-BSI (2.2%, 6.2%, and
11.7%; p = 0.026), but we observed no significant time
trends in antibiotic susceptibility for other antibiotic
regimens (Table 2). Proportions of non-susceptibility
by microbe are shown in Table 3. Non-susceptibility by
site of infection is shown in Additional file 1: Table S4.
Among seventy BSI episodes with microbes non-
susceptible to PGM (Fig. 3; Additional file 1: Table S5),
Candida spp. accounted for 17 episodes, E. coli 16, and
Enterococcus faecium and Staphylococcus epidermidis
for 9 episodes each. The great majority of episodes with
Candida spp., Enterococcus faecium or Staphylococcus
epidermidis occurred in HCA or HA-BSI, and the highest
numbers were recorded in the third time period. Regarding
E. coli not susceptible to PGM (which means not suscep-
tible to gentamicin), seven episodes occurred in CA,
eight in HCA, and one in HA-BSI. The number of E. coli
isolates non-susceptible to gentamicin was one (0.5%) in
2002–2005, six (2.6%) in 2006–2009, and nine (3.3%) in
2010–2013 (Additional file 1: Table S6).
The proportions of E. coli producing extended-
spectrum beta-lactamase (ESBL) were 0% in 2002–05,
Fig. 1 Distribution of microbes from 1995 bloodstream infection
episodes by place of acquisition. (Additional file 1: Table S1 shows
microbial agents by place of acquisition in more detail)
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Table 2 The proportion (%) of bloodstream infection (BSI) episodes with microbe(s) non-susceptible to some common antibiotic
regimens
Total 2002–2005a 2006–2009 2010–2013 p for trend
Penicillin-gentamicin
Total 6.1 4.4 6.1 7.5 0.011
Community acquired 4.3 2.2 5.7 5.0 0.22
Health care-associated 6.7 7.4 5.8 7.2 0.16
Hospital acquired 10.2 4.4 8.6 16.5 0.023
p for trend 0.006 0.058 0.46 0.003
Penicillin-gentamicin-metronidazole
Total 3.5 1.9 3.0 5.2 <0.001
Community acquired 1.4 0.3 1.8 2.1 0.28
Health care-associated 4.8 4.6 3.2 6.3 0.045
Hospital acquired 6.9 2.2 6.2 11.7 0.026
p for trend <0.001 0.007 0.15 0.001
Piperacillin/tazobactam
Total (n = 1413) 7.6 7.4 7.7 0.25
Community acquired (n = 617) 3.6 2.9 4.2 0.27
Health care-associated (n = 612) 8.8 9.4 8.4 0.31
Hospital acquired (n = 184) 8.8 9.4 17.0 0.31
p for trend <0.001 <0.001 <0.001
Piperacillin/tazobactam-gentamicin
Total (n = 1413) 3.0 2.4 3.6 0.21
Community acquired (n = 617) 1.0 0.7 1.2 0.69
Health care-associated (n = 612) 3.3 3.2 3.3 0.98
Hospital acquired (n = 184) 9.2 4.9 12.6 0.12
p for trend <0.001 0.037 <0.001
Piperacillin/tazobactam-gentamicin-metronidazole
Total (n = 1413) 2.6 1.7 3.4 0.065
Community acquired (n = 617) 0.5 0.0 0.9 0.26
Health care-associated (n = 612) 2.9 2.5 3.3 0.64
Hospital acquired (n = 184) 8.7 4.9 11.7 0.12
p for trend <0.001 0.004 <0.001
Imipenem
Community acquired 1.1 1.6 0.7 0.9 0.59
Health care-associated 6.5 9.1 5.8 5.7 0.39
Hospital acquired 10.6 11.1 7.4 12.6 0.14
p for trend <0.001 <0.001 0.001 <0.001
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2.0% in 2006–09, and 1.7% in 2010–13 (Additional
file 1: Table S7). Only one episode of methicillin-
resistant Staphylococcus aureus (MRSA) was found,
and only in two (0.9%) of 225 BSIs with Streptococcus
pneumoniae, the microbe was non-susceptible to penicillin
(Additional file 1: Table S3).
Initial empiric antibiotic therapy
The use of second- and third generation cephalosporins as
initial empiric therapy decreased through the study periods.
Cefuroxime was used as monotherapy or in combination in
19.6% and 5.3% of the BSI episodes in the first and in the
third time period, respectively. The corresponding propor-
tions for cefotaxime were 18.1% and 15.7% (Table 4). In
contrast, the use of ampicillin or penicillin plus genta-
micin increased from 14.1% to 19.9%. PIP/TAZ was
not used in the first period, but was the second most
used empiric therapy in the third period (17.3%). The
proportions of patients who received appropriate empiric
antibiotic therapy (AEAT) within 6 h and within 24 h
were larger in the third period than in the first and sec-
ond periods (Table 5). The proportions of patients
who received AEAT within 6 h in the third period
were 67.1% in CA, 67.2% in HCA, and 59.0% in HA-
BSI. The corresponding proportions who received AEAT
within 24 h were 88.4%, 84.4%, and 83.1%, respectively.
Discussion
In this prospective study of 1995 consecutive BSIs at a
medium-sized Norwegian hospital between 2002 and
2013, antimicrobial resistance was a far smaller problem
than reported in most studies [7, 17, 24, 25]. Except for
third-generation cephalosporins, antimicrobial resistance
to regimens recommended for sepsis of unknown eti-
ology was low. In less than 4% of BSI episodes, microbes
were non-susceptible to PGM, consistent with previous
findings at our hospital [26] and in other Norwegian
studies [10, 27]. However, the proportion of antibiotic
non-susceptibility was higher in HA and HCA than in
CA-BSI. For PGM, an increase in non-susceptibility
Table 2 The proportion (%) of bloodstream infection (BSI) episodes with microbe(s) non-susceptible to some common antibiotic
regimens (Continued)
Cefotaxime
Total 17.8 17.5 18.7 17.3 0.68
Community acquired 10.8 11.0 11.4 10.1 0.69
Health care-associated 21.3 25.1 22.7 18.2 0.18
Hospital acquired 31.4 25.6 29.6 37.9 0.31
p for trend <0.001 <0.001 <0.001 <0.001
Ceftazidime
Total 27.8 29.0 24.8 29.4 0.25
Community acquired 18.5 20.2 15.4 19.6 0.42
Health care-associated 31.3 36.0 28.2 31.3 0.37
Hospital acquired 49.6 46.7 45.7 55.3 0.46
p for trend <0.001 <0.001 <0.001 <0.001
aPiperacillin/tazobactam was not adopted in the first time period
The BSIs are stratified by place of acquisition and by time period (the total number in each cell is shown under the heading Place of acquisition in Table 1)
Fig. 2 Proportion of bloodstream infection microbes non-susceptible
to four antibiotic regimens by place of acquisition
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through the study period was observed in HA-BSI, mainly
caused by inherently resistant microbes. A slightly increas-
ing number of bacteria with acquired resistance was also
detected, particularly E. coli producing ESBL or possessing
gentamicin resistance. In our cohort, appropriate empiric
antibiotic therapy could be achieved to a larger extent by
replacing cephalosporins with PG or PIP/TAZ.
Strengths of this study include the prospective regis-
tration of BSIs within a well-defined area, and the hand-
ling of blood cultures at one microbiology laboratory.
We present susceptibility data by microbe, by place of
acquisition, and by site of infection. Most authors have
presented susceptibility data only by microbe, which is
generally unknown at the time the physician has to decide
on the initial antimicrobial therapy. We included microbes
with known inherent resistance in the presentation in
order to give guidance for empirical treatment before
the microbial etiology is known. Our use of one single
institution as the study site limits the generalizability of
our results, but regarding antibiotic resistance patterns as
basis for treatment guidelines, our results may be relevant
for other general hospitals in Scandinavia.
The low proportions of non-susceptibility in our BSI
microbes are likely explained by a relatively strict use of
antibiotics in Norway [8, 28, 29]. All antibiotics used in
humans are prescribed by physicians, and penicillins and
aminoglycosides are the preferred drugs in severe bacterial
infections. The increasing non-susceptibility in BSI
microbes by place of acquisition and, for HA-BSI, by time
period, was mainly due to a shift towards microbes with
natural (inherent) resistance, particularly Candida spp.,
Enterococcus faecium, and Staphylococcus epidermidis.
We attribute this shift to the increasing use of chemother-
apy and other immunosuppressive treatments (Additional
file 1, Table S9), which results in more prevalent infections
and antibiotic treatments, giving rise to selection of
Table 3 Proportions (%) of different microbes or microbe groups non-susceptible to some commonly recommended antibiotics
and antibiotic regimens
Microbe/microbe group Antibiotics and antibiotic combinations (2002–2013) P/T alone or in combinations
(2006–2013)
PG PGM Imi-penem Cefo-taxime Cefta-zidime Cipro-floxa-cin Total
N




0.9 0.9 0.0 0.4 0.4 NRT 226 0.7 0.7 0.7 146
Beta-hemolytic
streptococci
0.0 0.0 0.0 0.0 100.0 NRT 104 0.0 0.0 0.0 71
Viridans streptococci 0.0 0.0 0.0 3.5 8.8 NRT 57 0.0 0.0 0.0 42
Staphylococcus aureus# 0.5 0.5 0.0 0.0 100.0 (IR) NRT 218 0.0 0.0 0.0 146
Coagulase-negative
staphylococci
13.0 13.0 38.9 38.9 100.0 (IR) NRT 54 41.9 19.4 19.4 31
Enterococcus spp. 9.0 9.0 11.2 100.0 (IR) 100.0 (IR) NRT 89 11.5 9.8 9.8 61
Listeria monocytogenes 0.0 0.0 0.0 100.0 (IR) 100.0 (IR) NRT 8 0.0 0.0 0.0 6
Escherichia coli 1.9 1.9 0.1 1.9 1.9 3.3 686 6.0 0.8 0.8 500
Klebsiella spp. or Proteus
spp.
0.0 0.0 5.5 2.2 2.2 4.7 182 7.0 0.0 0.0 143
Other enterobacteria 1.4 1.4 9.5 20.3 21.6 2.9 74 16.9 100.0 100.0 59
Pseudomonas spp. 1.7 1.7 6.9 100.0
(IR)
3.4 8.2 58 5.3 2.6 2.6 38
Other aerobic
Gram-negatives
8.9 8.9 8.9 31.1 28.9 6.7 45 23.3 0.0 0.0 30
Anaerobic bacteria 66.1 3.6 0.0 96.4 96.4 NRT 56 5.1 7.7 0.0 39
Mixed bacterial infection 24.8 11.6 13.2 48.8 50.4 NRT 121 11.6 8.1 4.7 86













Total 6.1 3.5 4.5 17.8 27.8 NRT 1995 7.6 3.0 2.6 1413
§two isolates of penicillin-non-susceptible pneumococci were detected
#one single isolate of methicillin-resistant Staphylococcus aureus (MRSA) and one single isolate of gentamicin-resistant S. aureus were detected
IR, inherently resistant (see Additional file 1: Appendix 1 On inherent (natural) resistance in microbes); NRT, not routinely tested; PG, penicillin-gentamicin; PGM,
penicillin-gentamicin-metronidazole; P/T, piperacillin-tazobactam; P/T-G, piperacillin-tazobactam plus gentamicin; P/T-G-M, piperacillin-tazobactam plus gentamicin
plus metronidazole
Piperacillin-tazobactam (P/T) was adopted in 2006
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resistant microbes. A higher proportion of non-susceptible
microbes in HA and HCA than in CA-BSI is well known
from other studies [12, 13], but this cautionary knowledge
does not seem to have been sufficiently heeded by clinicians
and guideline makers. The national Norwegian surveillance
data on the distribution of different microbes isolated from
blood cultures show no time trend towards increasing
occurrence of natural resistant microbes from 2004 to 2014
[8, 30], but do not distinguish between CA, HCA, and HA
infection. The European Antimicrobial Resistance Surveil-
lance Network (EARS-Net) reported increasing occurrence
of Enterococcus faecium from 2002 to 2008 [7], but
Candida spp. and S. epidermidis are not included in the
EARS-Net surveillance.
Acquired resistance was uncommon in our BSI cohort,
but an increasing proportion of E. coli was non-susceptible
to gentamicin, and they occurred in CA as well as in HCA-
BSIs. Nationwide, a worrying increase in resistance to genta-
micin has emerged from 2003 to 2014 (0.6% to 7.7%) [8].
The EARS-Net has reported 5.2% and 9.9% aminoglycoside
resistance in E. coli in 2002 and 2013, respectively [7, 24],
but the proportion of aminoglycoside resistance was much
higher in the south-eastern region (32.1% in Bulgaria in
2013). The proportion of E. coli producing ESBL has
increased from 2008 to 2014 (1.5% to 5.8%) according
to the national data [8], and according to EARS-Net
data, the proportion of ESBL-producing E. coli in
Europe increased from 2.0% in 2002 [24] to 12.6% in
2013 (39.6% in Bulgaria) [7].
One single isolate of MRSA and two pneumococci
intermediately susceptible to penicillin were found in
our cohort. Nationwide, the proportion of MRSA in
blood cultures has been low in the corresponding time
period (0.3% and 0.8% in 2002 and 2014, respectively).
The low occurrence of MRSA in the Nordic countries
and in the Netherlands clearly distinguishes from the
other European countries, where MRSA accounted for
>25% of the S. aureus BSIs in 2007 [25] but had de-
creased to 18% in 2013 [7]. The nationwide proportion
of invasive pneumococci non-susceptible to penicillin
was 0.9% in 2002 and 5.5% in 2014 [8, 30]. In Europe,
the proportion of penicillin-non-susceptible isolates in
2013 ranged from 1.1% (the Netherlands) to 40.0%
(Cyprus) [7]. Comparisons of trends in acquired non-
susceptibility in the current study and in surveillance
Table 5 Appropriate empiric antibiotic therapy (AEAT) through







AEAT within 6 h
Community acquired BSI 61.7 63.4 67.1
Health care-associated BSI 64.0 53.6 67.2
Hospital acquired BSI 43.9 46.4 59.0
AEAT within 24 h
Community acquired BSI 84.2 89.4 88.4
Health care-associated BSI 76.7 81.3 84.4
Hospital acquired BSI 72.2 73.9 83.1
Percent of patients with bloodstream infection (BSI) receiving AEAT within 6 h
and within 24 h
Table 4 The most commonly used initial empiric antibiotic
regimens (percent) through three time periods






Cefotaxime 18.1 18.2 15.7
Penicillin/ampicillin-gentamicin 14.1 14.6 19.9
Penicillin 14.1 14.3 8.1
Piperacillin-tazobactam 0 8.6 17.3
Cefuroxime-metronidazole 9.8 8.1 4.1
Cefotaxime-metronidazole 3.6 5.6 5.5
Mecillinam 5.0 4.7 4.9
Cefuroxime 9.8 3.4 1.2
Penicillin-gentamicin-metronidazole 5.9 3.4 1.7
A complete table showing initial treatment in 1995 bloodstream infection
episodes is found in Additional file 1: Table S8
Fig. 3 Microbes non-susceptible to penicillin-gentamicin-metronidazole
(PGM) through three time periods. (Additional file 1: Table S5
shows the PGM non-susceptible microbes in detail) ANS, acquired
non-susceptibility; INS, inherent non-susceptibilty
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data from Norway and other European countries are
shown in Table 6.
Empirical antibiotic treatment regimens have to be con-
tinuously evaluated in accordance with national and local
microbe resistance patterns. The initial empiric treatment
for sepsis of unknown origin recommended by the Na-
tional Professional Guidelines for Use of Antibiotics in
Hospitals in Norway consists of penicillin and gentamicin,
plus metronidazole (PGM) if an anaerobic infection is sus-
pected [11]. PGM was not effective in vitro against 3.5%
of the microbes isolated from blood cultures in the
present study. In patients with HA-BSI, however, the pro-
portion of microbes not susceptible to PGM was 11.7% in
the third time period. In defined subgroups we have to be
aware of PGM resistant microbes and include vancomycin
(e.g., suspected central venous catheter infection) or an
antifungal drug (if suspected candida infection, e.g., long
lasting broad-spectrum antibiotic therapy, long time stay
in a ICU, particularly after gastrointestinal surgery), in our
recommendations. Use of carbapenems in empiric therapy
should be restricted to patients infected with bacteria re-
sistant (known or suspected) to PIP/TAZ and in whom
aminoglycoside therapy is contraindicated.
Enterococci are inherently resistant to cephalosporins
and staphylococci are not susceptible to ceftazidime. In
our BSI cohort, staphylococci and enterococci contributed
to 30% of HA-BSI episodes. Noteworthy, the percentages
of microbes non-susceptible to cefotaxime and ceftazi-
dime in HA-BSI in the third period were as high as 37.9
and 55.3%, respectively. Therefore, none of these appears
suitable for use as monotherapy in sepsis of unknown mi-
crobial origin. The emergence of ESBL in Gram-negative
bacteria has made it even more risky to choose a third-
generation cephalosporin as monotherapy for severe
infections with unknown etiology.
Even though the National Professional Guidelines [11]
recommend PG (or PGM) as the regimen of first choice
in sepsis of unknown etiology, the PG (or PGM) combin-
ation was given in no more than 20% of the episodes in
our BSI cohort, yet the proportion was increasing with
time. There are mainly two reasons for prescribing anti-
biotic treatment that does not include an aminoglycoside:
(1) Aminoglycosides are potentially nephrotoxic and oto-
toxic. Therefore, there is a tendency to avoid them even in
cases where they should not be contraindicated. (2) Use of
an aminoglycoside requires measurement of amino-
glycoside serum concentrations, which is resource
consuming, and knowledge and experience is needed
for assessment of the results. In a busy day, it is
much simpler to administer a beta-lactam-antibiotic,
where dosing is simple and the risk of toxicity is
negligible.
In Norway, we lack national data for antibacterial treat-
ment given in cases of bloodstream infection or sepsis.
Table 6 Comparisons of trends in acquired non-susceptibility in Escherichia coli, Staphylococcus aureus, and Streptococcus
pneumoniae
Microbe Type of non-susceptibility Surveillance Area Trends in proportions of non-susceptibility (Time period)
E. coli Gentamicin non-susceptibility Levanger Hospital 0.5% (2002–05) 3.3% (2010–13)
Iceland 2.9% (2010) 4.1% (2013)
Norway 0.6% (2003) 7.7% (2014)
EU/EEA 5.2% (2002) 9.9% (2013)
Bulgaria 15.8% (2003) 32.1% (2013)
E. coli Resistance to 3rd generation cephalosporins Levanger Hospital 0 (2002–05) 1.7% (2010–13)
Norway 1.5% (2008) 5.8% (2014)
EU/EEA 2.0% (2002) 12.6% (2013)
Bulgaria 24.8% (2010) 39.6% (2013)
S. aureus MRSA Levanger Hospital 0 (2002–05) 1.0% (2010–13)
Norway 0.3% (2002) 0.8% (2014)
EU/EEA 25.6% (2007) 18.0% (2013)
Malta 52.0% (2007) 51.8% (2013)
Romania 39.1% (2010) 64.5% (2013)
S. pneumoniae PNSP Levanger Hospital 0 (2002–05) 3.0% (2010–13)
Netherlands 2.0% (2010) 1.1% (2013)
Norway 0.9% (2002) 5.5% (2014)
Cyprus 41.7% (2010) 40.0% (2013)
MRSA, meticillin-resistant Staphylococcus aureus; PNSP, penicillin non-susceptible pneumococci
Proportions of non-susceptibility from the current study (Levanger Hospital) are compared with data from Norway (the national surveillance system [8, 30], the
European Union/the European Economic Area (EU/EEA), and with countries which have extraordinary low or high proportions of non-susceptibility [7, 24, 25]
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Regarding antibiotic use in Norwegian hospitals, the
national surveillance data [8] show that the propor-
tion of aminoglycoside use was less than 5% in 2015
(3.3 out of 73 DDD/100 bed-days), indicating that avoiding
aminoglycosides in favor of beta-lactam antibiotics is
a common mode of acting countrywide.
The drawback of avoiding aminoglycosides is increased
risk of antimicrobial resistance, as particularly cephalospo-
rins are far more resistance driving than aminoglycosides.
Therefore, a further shift in favor of aminoglycosides is
desirable. As the use of aminoglycosides in our hospital
and nationwide is still relatively low, overuse of aminogly-
cosides is unlikely to explain the observed increase in
non-susceptibility to gentamicin in E. coli.
During the three time periods, we observed that the use of
second- and third- generation cephalosporins decreased,
whereas ampicillin or penicillin plus gentamicin were more
frequently given. PIP/TAZ was introduced at our hospital in
2006, and the use of it has been increasing, particularly in
the third period. Nationwide, the use of aminoglycosides and
particularly piperacillin/tazobactam has increased during the
last ten years, whereas the use of second-generation cephalo-
sporins has decreased. The use of third-generation cephalo-
sporins and fluoroquinolones peaked in 2011–2012 and have
since then declined [8]. These changes are in accordance
with the national [11] and local antibiotic policy, in
order to achieve regimens that are less resistance driving
and also cover the BSI microbes to a larger extent.
Conclusions
Antimicrobial resistance was a far smaller problem in
our BSI cohort than is reported from countries outside
Scandinavia. The antibiotic regimen recommended by
Norwegian Health Authorities [11], consisting of penicillin
and gentamicin, and with metronidazole added when an
anaerobic infection is suspected, is so far effective in vitro
against a great majority of microbes isolated from BSI
patients in this region. In our cohort, appropriate empiric
antibiotic therapy was achieved to a larger extent by
replacing second- and third-generation cephalosporins
with penicillins and gentamicin. We must, however, be
aware of an increasing occurrence of inherently resistant
microbes, particularly in HA infection. There are also
indications of increasing numbers of bacteria with acquired
resistance, particularly E. coli producing ESBL and/or
possessing gentamicin resistance, and these occurred
predominantly in CA and HCA infections.
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